ArticleInternational neurourology journal2025
The Role of Urinary Secretory Immunoglobulin A in the Pathophysiology of Interstitial Cystitis.
Article in International neurourology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Urinary Biomarkers in Interstitial Cystitis and Bladder Pain Syndrome: A Narrative Review of Differential Diagnosis and Treatment Monitoring.International urogynecology journal · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aimed to determine whether urinary secretory immunoglobulin A (sIgA) levels differ between patients with bladder pain syndrome/interstitial cystitis (BPS/IC) and healthy controls, and to assess whether urinary sIgA is linked to mucosal immune mechanisms that may contribute to BPS/IC pathophysiology.
methodsA single-center, cross-sectional study was conducted between April and June 2020 at the Department of Urology, Ege University Faculty of Medicine. Forty female patients with BPS/IC and 40 healthy controls were enrolled. Symptom severity in the BPS/IC group was evaluated using the O'Leary-Sant Interstitial Cystitis Symptom and Problem Index. Patients with active urogenital infections, a history of bladder cancer, or prior pelvic radiotherapy were excluded. Urine samples were collected in sterile containers, centrifuged, and stored at -80°C before sIgA measurement using a commercial enzyme-linked immunosorbent assay kit. Correlations between continuous variables were examined with Spearman rank correlation coefficients.
resultsUrinary sIgA levels were not significantly different between the BPS/IC group (mean±standard deviation: 0.96±1.5 μg/mL) and healthy controls (0.53±0.7 μg/mL) (P=0.173). Subgroup analyses within the BPS/IC cohort showed that smokers had significantly lower urinary sIgA levels (median [range], 0.001 [0.000-0.082] μg/mL) compared with nonsmokers (median [range], 0.720 [0.000-6.850] μg/mL) (P=0.004). Conversely, patients with cardiac comorbidities had significantly higher urinary sIgA levels (median [range], 0.820 [0.100-6.850] μg/mL) than those without cardiac disease (median [range], 0.213 [0.000-2.300] μg/mL) (P=0.015).
conclusionAlthough no significant differences in urinary sIgA levels were observed between BPS/IC patients and healthy controls, subgroup analyses identified associations with smoking and cardiac comorbidities. These findings suggest that sIgA may be relevant to BPS/IC pathophysiology and highlight the potential of mucosal immune biomarkers. Larger studies are warranted to further clarify the role of sIgA in BPS/IC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.